Robinson, Simon
May 2006
ICIS Chemical Business;5/29/2006, Vol. 1 Issue 21, p10
Trade Publication
The article presents updates on the chemical industry in Europe. A dispute between energy group RAG and the German government threatens the timetable for an initial public offering of RAG in the fourth quarter of 2007 and creates uncertainty for Degussa. The European Union competition authority approved Bayer's planned friendly takeover of Schering, and did not impose any conditions on the move. A forecast claims that Dutch chemicals turnover will increase by 6% in 2006, driven by rises in output volume and higher prices.


Related Articles

  • Europe Watch. Robinson, Simon // ICIS Chemical Business;7/17/2006, Vol. 1 Issue 28, p10 

    The article presents an update on issues related to the chemical industry. Bayer was able to own 92.4 percent of Schering after July 6, 2006 closure. German energy group RAG plans to decrease few administrative jobs when it merges the holdings of chemical producer Degussa, power plant operator...

  • Too little, too late? Abbot, Alison // Nature;3/30/2006, Vol. 440 Issue 7084, p603 

    The article examines the merger activity in the pharmaceutical industry in Germany. It details Bayer AG's offer to buy Schering AG. According to pharmaceutical analysts, the merger will affect mid-sized drug companies. There are three ways for these companies to respond according to a report...

  • Bayer Makes Schering Offer Official; Schering Recommends Bid.  // Chemical Week;4/26/2006, Vol. 168 Issue 14, p5 

    The article reports on the official bid price for the acquisition of Schering released by Bayer in April 2006. According to Bayer, there is approximately €3 billion in liquidity available to finance the acquisition. The acquisition would increase the sales of Bayer that were generated by...

  • Consolidations, spinoffs shape business climate.  // Fairfield County Business Journal;02/28/2000, Vol. 39 Issue 9, p12 

    Focuses on the trends that will shape the business climate in Connecticut in 2000. Volatility due to Internet stocks; Shortage of capital for non-Internet initial public offerings; Mergers between banks, insurers and brokers; Competing takeovers by consolidating industries before deals are...

  • News in brief.  // Nature Reviews Drug Discovery;Jul2006, Vol. 5 Issue 7, p530 

    The article presents news briefs related to the recent developments in the pharmaceutical industry. Merck & Co. Inc.'s cervical cancer vaccine Gardasil has successfully passed the regulatory and scientific hurdles, but other hurdles might prove to be more problematic. Studies have shown that the...

  • Bayer meets Schering target.  // ICIS Chemical Business;6/19/2006, Vol. 1 Issue 24, p10 

    The article reports on the success of Bayer in meeting its target of acquiring at least 75% of German pharmaceutical group Schering. At an estimated € 17bn, the Schering buy will cost Bayer € 500m more than first calculated. The last-minute reentry of German pharma and chemicals...

  • Bayer Schering job cuts. William, Dede; Gibson, Jane // ICIS Chemical Business Americas;3/5/2007, Vol. 271 Issue 9, p13 

    This article reports that Schering is set to cut 950 jobs at its headquarters in Berlin, Germany by 2009. Werner Wenning, Bayer chairman, said the move is due to the merger between the pharmaceutical activities of Schering and Bayer. Wenning, who is also chairman of Bayer Schering Pharma's...

  • Bayer Clinches Acquisition of Schering.  // Chemical Week;6/28/2006, Vol. 168 Issue 22, p5 

    The article reports on the acquisition of Schering by Bayer as of June 28, 2006. Shareholders representing majority of Schering's equity had accepted Bayer's offer by June 20. Bayer will merge its pharmaceuticals business with Schering to form Bayer Schering Pharma in Berlin, Germany. Its...

  • Pharma troubles are bitter pill. Williams, Dede // ICIS Chemical Business;3/17/2008, Vol. 273 Issue 11, p12 

    The article presents information on several problems faced by Bayer AG, a pharmaceutical firm headquartered in Leverkusen, Germany. It states that even though the firm seems to have revitalized its healthcare franchise Bayer HealthCare AG with the acquisition of pharma research firm Schering AG...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics